CRBN and plasma cell myeloma: Furthermore, in the progression free survival (PFS) analysis, newly diagnosed multiple myeloma (NDMM) individuals who underwent IMiD-based treatment regimen, and in whom a hypermethylation of CRBN enhancer was detected, had an inferior PFS [55].